Inhibition of Glucose-6-Phosphate Dehydrogenase Activity Attenuates Right Ventricle Pressure and Hypertrophy Elicited by VEGFR Inhibitor + Hypoxia

Atsushi Kitagawa, Christina Jacob, Allan Jordan, Ian Waddell, Ivan F. McMurtry, and Sachin A. Gupte

Department of Pharmacology, New York Medical College, Valhalla, New York (A.K., C.J., S.A.G.); Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Macclesfield, United Kingdom (A.J., I.W.); and Departments of Pharmacology and Internal Medicine and Center for Lung Biology, College of Medicine, University of South Alabama, Mobile, Alabama (I.F.M.)

Received June 12, 2020; accepted February 16, 2021

ABSTRACT
Pulmonary hypertension (PH) is a disease of hyperplasia of pulmonary vascular cells. The pentose phosphate pathway (PPP)—a fundamental glucose metabolism pathway—is vital for cell growth. Because treatment of PH is inadequate, our goal was to determine whether inhibition of glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the PPP, prevents maladaptive gene expression that promotes smooth muscle cell (SMC) growth, reduces pulmonary artery remodeling, and normalizes hemodynamics in experimental models of PH. PH was induced in mice by exposure to 10% oxygen (Hx) or weekly injection of vascular endothelial growth factor blocker [Sugen5416 (SU); 20 mg kg\(^{-1}\)] during exposure to hypoxia (Hx + SU). A novel G6PD inhibitor (N\(\text{[(3b,5a)-17-oxoandrostan-3-yl]}\)sulfamide; 1.5 mg kg\(^{-1}\)) was injected daily during exposure to hypoxia (Hx + SU). We measured right ventricle (RV) pressure and left ventricle pressure-volume relationships and gene expression in lungs of normoxic, Hx, and Hx + SU and G6PD inhibitor–treated mice. RV systolic and end-diastolic pressures were higher in Hx and Hx + SU than normoxic control mice. Hx and Hx + SU decreased expression of epigenetic modifiers (writers and erasers), increased hypomethylation of the DNA, and induced aberrant gene expression in lungs. G6PD inhibition decreased maladaptive expression of genes and SMC growth, reduced pulmonary vascular remodeling, and decreased right ventricle pressures compared with untreated PH groups. Pharmacologic inhibition of G6PD activity, by normalizing activity of epigenetic modifiers and DNA methylation, efficaciously reduces RV pressure overload in Hx and Hx + SU mice and preclinical models of PH and appears to be a safe pharmacotherapeutic strategy.

SIGNIFICANCE STATEMENT
The results of this study demonstrated that inhibition of a metabolic enzyme efficaciously reduces pulmonary hypertension. For the first time, this study shows that a novel inhibitor of glucose-6-phosphate dehydrogenase, the rate-limiting enzyme in the fundamental pentose phosphate pathway, modulates DNA methylation and alleviates pulmonary artery remodeling and dilates pulmonary artery to reduce pulmonary hypertension.

Introduction
Pulmonary hypertension (PH) is a multifactorial disease that is defined as sustained elevation of pulmonary arterial pressure (Farber and Loscalzo, 2004). The elevation of pulmonary arterial pressure increases right ventricular (RV) afterload, leading to heart failure and death (Runo and Loyd, 2003). The main vascular changes in PH are vasoconstriction, vascular cell proliferation, and thrombosis. Based on these findings, current standard of care is treatment with vasodilators. However, vasodilators such as endothelin receptor blockers, nitric oxide/nitrates, prostacyclin, and phosphodiesterase-5 inhibitors fail to reverse vascular remodeling, and the long-term prognosis remains poor (Lajoie et al., 2016).

Based on WHO classification, PH is divided into five groups. WHO group 1 is pulmonary arterial hypertension, group 2 is PH from left-heart disease, group 3 is PH from chronic hypoxic lung disease, group 4 is PH from chronic blood clots, and group 5 is PH from unclear multifactorial mechanisms (sarcoidosis, hematologic disorders, etc.). The pathogenesis of PH (group 1 ABBREVIATIONS: Dnmt, DNA methyltransferase; G6PD, glucose-6-phosphate dehydrogenase; Hx, hypoxia; IPA, isolation of small intrapulmonary artery; LVEDP, left ventricle end-diastolic pressure; LVSP, left ventricle end-systolic pressure; mAP, systemic mean arterial pressure; PASMC, pulmonary artery smooth muscle cell; PDD4091, N\(\text{[(3b,5a)-17-oxoandrostan-3-yl]}\)sulfamide; PH, pulmonary hypertension; PPP, pentose phosphate pathway; RV, right ventricle; RVEDP, RV end-diastolic pressure; RVSP, RV systolic pressure; SMC, smooth muscle cell; SU, Sugen5416; Tet, ten-eleven translocation.
and group 2) is still unclear. PH occurs under sustained environmental stress such as inflammation, shear stress, and hypoxia. These stress stimuli contribute to the shifting of pulmonary vascular cells to hyperproliferative and apoptotic-resistant phenotypes, allowing abnormal vascular remodeling and PH development (Boucherat et al., 2017; D’Alessandro et al., 2018). Pulmonary vascular cells in patients with PH also undergo metabolic adaptation to support their high rate of proliferation or inadequate rates of mitotic fission. This metabolic shift, the Warburg phenomenon (Warburg et al., 1927), is a failure of mitochondrial respiration and activation of aerobic glycolysis.

The pentose phosphate pathway (PPP)—a branch of glycolysis and a fundamental glucose metabolism pathway—is vital for cell growth and survival. Glucose-6-phosphate dehydrogenase (G6PD) is the first rate-limiting enzyme of the PPP. G6PD and the PPP generate pentose sugar, which is required for the de novo cellular synthesis of RNA and DNA, and NADPH, a key cofactor for reductive and anabolic reactions. Recently, we found that inhibition and knockdown of G6PD in lungs of a chronic hypoxia–induced PH mouse model reduced and reversed 1) the Warburg phenomenon, 2) epigenetic modification (DNA methylation), 3) maladaptive expression of genes that support pulmonary artery remodeling, and 4) PH and left-heart dysfunction (Joshi et al., 2020). However, the role of G6PD in the pathogenesis of hypoxia + Sugen5416–induced PH is unknown. Furthermore, whether inhibition of G6PD reduces remodeling of pulmonary artery and PH in the hypoxia + Sugen5416 mouse model remains to be determined. We hypothesized that G6PD is a safe pharmacotherapeutic target to reduce PH in the hypoxia + Sugen5416 mouse model. Therefore, our objectives were to determine whether the inhibition of G6PD activity by pharmacologic manipulations would decrease differential DNA methylation and maladaptive gene expression in lungs and pulmonary vascular cells, reduce vascular remodeling, and normalize hemodynamics in models of chronic hypoxia– and hypoxia + Sugen5416–induced PH (groups 3 and 1, respectively).

Materials and Methods

Drugs and Reagents. All chemicals and reagents were purchased from Sigma, Thermo Fisher Scientific, and VWR.

Animal Models and Experimental Protocols. All animal experiments were approved by the New York Medical College Animal Care and Use Committee, and all procedures conformed to the guidelines from the NIH Guide for the Care and Use of Laboratory Animals. Male and female C57BL/6J mice (18–32 g) were purchased from the Jackson Laboratory and were randomly divided into four groups: normoxia (Nx), normoxia + Sugen5416 (Nx + SU), hypoxia (Hx), and hypoxia + Sugen5416 (Hx + SU) groups. Mice in the Nx group were placed in a normoxic (21% O2) environment, and mice in the Hx group were placed in a normobaric hypoxic chamber (10% O2) for 6 weeks (Joshi et al., 2020). Mice in the Nx + SU and Hx + SU groups received subcutaneous injection of SUG5416 (20 mg/kg) once weekly during 3 weeks of Nx (21% O2) or Hx (10% O2) as previously described (Vitali et al., 2014). Mice in the drug treatment groups received daily subcutaneous injection of a novel G6PD inhibitor, N-[(3S,5a)-17-oxoandrostan-3-yl]sulfamide (PDD4091; 1.5 mg kg⁻¹ day⁻¹) (Hamilton et al., 2012), for 3 weeks. To determine whether PDD4091 reduces PH in a dose-dependent manner, mice were randomized to receive low-dose (0.15 mg kg⁻¹ day⁻¹), medium-dose (1.5 mg kg⁻¹ day⁻¹), or high-dose (15 mg kg⁻¹ day⁻¹) injections of PDD4091. Hx and Hx + SU mice are preclinical models of PH (Stenmark et al., 2009). At the end of the treatment period, hemodynamic measurements were performed, tissue (lungs and arteries) was harvested, and blood samples were collected. Data analysis was performed in a blinded fashion.

Hemodynamic Measurements. All mice were anesthetized with inhalation of isoflurane (isoflurane, USP; 1-chloro-2,2,2-trifluoroethyl difluoromethyl ether; induced at 3% and maintained at 1.5%) and placed on a heated table. Closed-chest cardiac catheterization was performed using an MPVS Ultra Single Segment Pressure-Volume Unit (Millar Instruments) in combination with a cardiac catheter. RV systolic pressure (RVSP) and RV end-diastolic pressure (RVEDP) were measured by catheterization of the RV via the right external jugular vein using Millar Mikro-Tip catheter (model SPR-671, tip size of 1.4F; Millar Instruments). The catheter was then removed, and the jugular vein was tied off. For hemodynamic measurements from LV, the right carotid artery was dissected, and a Millar Mikro-Tip conductance catheter (model SPR-839, tip size of 1.4F; Millar Instruments) was introduced into the artery and advanced into the LV via the aortic valve. Once steady-state hemodynamics were achieved, pressure-volume loops were recorded and analyzed using LabChart 8 software (ADInstruments).

Hematocrit Measurements and Blood Chemistry Analysis. After hemodynamic measurements were completed, blood was collected from the cardiac chambers into a heparinized syringe. Heparinized blood was placed in capillary tubes, and hematocrit (%) was calculated as the length of the erythrocyte layer divided by the length of the entire blood sample. Plasma was shipped to Antech Diagnostics (NC), a GLP facility, where blood tests were performed with routinely used clinical laboratory diagnostic tools.

Assessment of Right Ventricular Hypertrophy. After the cardiac catheterization, the animals were euthanized by cervical dislocation, whole hearts were excised, and RV free wall and LV including ventricular septum (S) were separated and weighed independently. Fulton’s index (RV/LV + S ratio) was calculated as an index of RV hypertrophy.

Isolation of Small Intrapulmonary Arteries and IPA Tone Measurements. Mice (25–30 g) were sacrificed by cervical dislocation, and small intrapulmonary arteries (IPA) of third order (100–150 μm in diameter) were isolated from the lung, dissected free of connective tissue, and placed in Krebs’ bicarbonate buffer solution (pH 7.4) containing the following (in millimolars): 118 NaCl, 4.7 KCl, 1.5 CaCl₂ × 2H2O, 25 NaHCO₃, 1.1 MgSO₄, 1.2 KH₂PO₄, 5.6 glucose, and 10 HEPES. Then, the vessels were mounted on a wire myograph (Danish Myo Technology A/S, Aarhus, Denmark) and bathed in Krebs’ buffer solution at 37°C and an optimal passive tension of 3 mN. After 30 minutes of incubation, the arterial viability and equilibration were assessed by the stimulation of the vessels with repeated 10-minute exposures to KCl (60 mM; 60 K). For registration of vascular ring contractile activity and its following analysis, Chart 5.5.4 and LabChart Reader 8.1.9 (ADInstruments, Inc.) software were used. Vascular tension is presented as a percentage of the maximum steady-state contraction level obtained to the exposure to 60 K.

RNA-seq Analysis. After collecting lungs from Nx, Hx, and Hx + SU mice, total RNA was isolated from tissue using the Qiagen All Prep DNA/RNA/miRNA Universal kit according to manufacturer’s instructions. RNA was quantified using the NanoDrop (Thermo Fisher Scientific), and quality was assessed using the Agilent Bioanalyzer 2100. RNA-seq library construction was performed using the TruSeq Stranded Total RNA Preparation kit (Illumina) with 200 ng of RNA as input according to the manufacturer’s instructions. Libraries were sequenced on the HiSeq2500 with single-end reads of 100 nt at the University of Rochester Genomics Research Center. Single-end sequencing was done at a depth of 10 million reads per replicate. Quantitative analysis, including statistical analysis of differently expressed genes, was done with Cufflinks 2.0.2 and Cuffdiff2 (http://cufflinks.cbcb.umd.edu). The Benjamini-Hochberg method was applied for multiple test correction (FDR < 0.05).

Reduced Representation Bisulfite Sequencing. To determine DNA methylation status in lungs of Nx, Hx, Hx + SU, and Hx + 4091
mice, genomic DNA was isolated from lungs using the Qiagen All Prep DNA/RNA/miRNA Universal kit according to the manufacturer’s instructions. DNA was quantified using the NanoDrop (Thermo Fisher Scientific) and Qubit Fluorometer (Thermo Fisher Scientific). Genomic DNA quality was assessed using the Agilent TapeStation. Reduced representation bisulfite sequencing library construction was performed with the Premium Reduced Representation Bisulfite Sequencing Kit (Diagenode) following the manufacturer’s instructions. Libraries were sequenced on the HiSeq2500 with paired-end reads of 125 nt. Raw reads generated from the Illumina HiSeq2500 sequencer were de-multiplexed using bcl2fastq version 2.19.0. Quality filtering and adapter removal are performed using Trim Galore version 0.4.4.dev with the following parameters: “–paired–clip_R1 3–clip_R2 3–three_prime_clip_R1 2–three_prime_clip_R2 2” (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). Processed and cleaned reads were then mapped to the mouse reference genome (mm9) using Bismark version 0.19.0 with the following parameters: “--bowtie2--maxins 1000.” Differential methylation analysis was performed using methylKit version 1.4.0 within an R version 3.4.1 environment. Bismark alignments were processed via methylKit in the CpG context with a minimum quality threshold of 10. Coverage was normalized after filtering for loci with a coverage of at least five reads and no more than the 99.9th percentile of coverage values. The coverage was then normalized across samples, and the methylation counts were aggregated for 500-nt windows spanning the entire genome. A unified window set across samples was derived such that only windows with coverage by at least one sample per group were retained. Differential methylation analysis between conditional groups was performed using the $r^2$ test and applying a $q$-value (SLIM) threshold of 0.05 and a methylation difference threshold of 25%.

**Quantitative Real-Time PCR.** Real-time RT-PCR technique was used to analyze mRNA expression. Briefly, total RNA was extracted from lungs using a Qiagen miRNEasy kit (217004). The input RNA quality and concentration were measured on the Synergy HT Take3 Microplate Reader (BioTek, Winooski, VT), and cDNA was prepared using SuperScript IV Vilo Master Mix (11756500; Invitrogen) for mRNA. Quantitative PCR was performed in duplicate using TaqMan Fast Advanced Master Mix (44-445-57) for mRNA using a Mx3000p Real-Time PCR System (Stratagene, Santa Clara, CA). The primers for the qPCR were purchased from Thermo Fisher Scientific/TaqMan. Results for mRNA expression were normalized to internal control $Tuba1a$, and relative mRNA expression was determined using the $\Delta$Ct method.

**Cell Culture.** Human pulmonary artery smooth muscle cells (PASMCs; Lonza) were maintained at 37°C under 5% CO$_2$ in smooth muscle basal media (CC-3181; Lonza) supplemented with growth factors (SMGM-2 smooth muscle singlequots kit, CC-4149; Lonza). Once cells reached approximately 70% confluence, they were subcultured using 0.05% trypsin-EDTA (25300-054; GibCO, Thermo Fisher Scientific, Grand Island, NY) into six-well plates at about 3 x 10$^5$ cells per well.

**Statistical Analysis.** Statistical analysis was performed using GraphPad Prism 5 software. Values are presented as means ± S.E. Statistical comparisons of samples were performed with two-way ANOVA followed by Sidak’s post hoc test for multiple comparisons and Student’s t test for comparing two groups. Differences with $P < 0.05$ between the groups were considered significant.

**Results**

**G6PD Inhibition Decreased Chronic Hx- and Hx + SU-Induced PH in Mice.** PH was induced by exposing C57BL/6J mice to Hx and Hx + SU (Fig. 1A). C57BL/6J mice exposed to Hx and Hx + SU had higher RVSP and RVEDP than Nx mice (Fig. 1B). In the Nx + SU group, as compared with the Nx group, RVSP (Nx + SU: 24.6 ± 0.9 vs. Nx: 23.2 ± 1.3; mm Hg) and RVEDP (Nx + SU: 4.0 ± 0.4 vs. Nx: 3.8 ± 0.4; mm Hg) were not different. In the Hx + SU group, RVSP and RVEDP were higher than those of the Hx group (Fig. 1B).

To determine whether G6PD inhibition reduces PH, we first established the maximum tolerated dose of G6PD inhibitor (PDD4091). The maximum tolerated dose in Hx mice was 15 mg kg$^{-1}$ day$^{-1}$, beyond which PDD4091 depressed LV function. More importantly, treatment with the G6PD inhibitor PDD4091 to Hx mice decreased the elevated RVSP and RVEDP in a dose-dependent manner (Fig. 1, B and C, top panel).
PDD4091 had a reasonably wide therapeutic window (0.01–15 mg kg⁻¹ day⁻¹) with an EC₅₀ of 0.26 ± 0.10, and 0.58 ± 0.36 mg kg⁻¹ day⁻¹ reduced both RVSP and RVEDP. Moreover, PDD4091 (1.5 mg kg⁻¹ day⁻¹) treatment to both Hx and Hx + SU mice efficaciously reduced the elevated RVSP and RVEDP (Fig. 1, A and C, bottom panel). Fulton’s index was increased in Hx and Hx + SU groups as compared with Nx and Nx + SU groups. G6PD inhibitor reduced elevated Fulton’s index in Hx and Hx + SU groups (Table 1). In addition, PDD4091 (1.5 mg kg⁻¹ day⁻¹) treatment to mice (n = 6) with preexisting Hx + SU-induced PH reduced RVSP (from Hx + SU: 74 ± 5.3 to Hx + SU + PDD4091: 41 ± 3.3 mm Hg; P < 0.05), RVEDP (from Hx + SU: 13 ± 3 to Hx + SU + PDD4091: 7 ± 1 mm Hg; P < 0.05), and Fulton’s index (from Hx + SU: 0.4 ± 0.01 to Hx + SU + PDD4091: 0.3 ± 0.01; P < 0.05). PDD4091 (1.5 mg kg⁻¹ day⁻¹) reduced G6PD activity by 20%.

RV dP/dt had a tendency to increase in the Hx group compared with Nx and significantly increased in Hx + SU compared with Nx. PDD4091 treatment (1.5 mg kg⁻¹ day⁻¹; Table 1) normalized RV dP/dt in the Hx + SU group. LV hemodynamic and function parameters are shown in Table 2. There were no significant differences in mAP, LVSP, LVEDP, and dP/dt min in the Hx and Hx + SU groups (Table 1). In addition, PDD4091 dose-dependently relaxed PA precontracted with KCl (Fig. 2A). Application of PDD4091 [1 μmol/L, an EC₅₀ dose (Hamilton et al., 2012)] for 48 hours to PASMCs cultured in normoxia decreased cell numbers (Fig. 2B) and in addition attenuated the cell growth evoked by Hx and Hx + SU (Fig. 2C). Treatment of Hx + SU mice with PDD4091 (1.5 mg kg⁻¹ day⁻¹) for 3 weeks abrogated the occlusive pulmonary vascular remodeling (Fig. 2D).

**Gene Expression Is Altered in Lungs of Hx and Hx + SU Mice.** To discover the genetic and/or epigenetic determinants of PASMC growth in the PA wall and remodeling of PA in Hx and Hx + SU, we performed RNA-seq analysis in lungs of mice exposed to Hx, Hx, and Hx + SU. Several thousand genes (total 33,141) were upregulated (15,412) or downregulated (17,729) in lungs of mice exposed to Hx and Hx + SU as compared with Nx. The results revealed that out of 159 and 97 genes upregulated (≥1.5log₂ fold; P < 0.05) in lungs of Hx versus Nx and Hx + SU versus Nx mice, respectively, only three genes were commonly upregulated in both groups (Fig. 3A), whereas out of 1511 and 1523 genes that were downregulated (≤−1.5log₂ fold; P < 0.05) in lungs of Hx versus Nx and Hx + SU versus Nx mice, respectively, 1085 genes were commonly downregulated in both groups (Fig. 3A). Transcription factor binding site enrichment analysis using oPOSSUM (Kwon et al., 2012) disclosed TCFCP2l1, KLF4, and E2F1 as the most enriched TFBS in Hx vs Hx + SU and Hx vs Nx.

**G6PD Inhibition Relaxed Precontracted PA, Decreased PASMC Growth, and Reduced PA Remodeling in Hx + SU Mice.** PA remodeling is the hallmark of severe PH. Hyperplastic and apoptosis-resistant PA endothelial cells and PASMCs contribute to hypertensive remodeling (Morrell et al., 2009). Previously, we and others proposed that PASMCs switch from a differentiated to a dedifferentiated phenotype in PA of hypertensive patients and animals and contribute to PA remodeling (Zhou et al., 2009; Chettimada et al., 2015; Sahoo et al., 2016). Dedifferentiated SMCs are hyperproliferative, migratory, and secretory (Frismani et al., 2018). Previous studies show that the Hx + SU mouse model of PH has more severe PA remodeling than Hx mice (Vitali et al., 2014).

Downloaded from jpet.aspetjournals.org at ASPET Journals on August 8, 2021

**TABLE 1**

<table>
<thead>
<tr>
<th></th>
<th>Nx (n = 11)</th>
<th>Nx + 4091 (n = 6)</th>
<th>Hx (n = 9)</th>
<th>Hx + 4091 (n = 11)</th>
<th>SuHx (n = 7)</th>
<th>SuHx + 4091 (n = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>b.wt. (g)</td>
<td>23 ± 3</td>
<td>26 ± 5</td>
<td>24 ± 3</td>
<td>23 ± 3</td>
<td>25 ± 3</td>
<td>26 ± 2</td>
</tr>
<tr>
<td>HR (bpm)</td>
<td>455 ± 71</td>
<td>508 ± 71</td>
<td>455 ± 36</td>
<td>466 ± 34</td>
<td>519 ± 19</td>
<td>468 ± 52</td>
</tr>
<tr>
<td>mAP (mm Hg)</td>
<td>87.7 ± 12.4</td>
<td>76.5 ± 4.0*</td>
<td>88.3 ± 6.7</td>
<td>85.4 ± 4.8</td>
<td>82.9 ± 15.3</td>
<td>85.0 ± 4.0</td>
</tr>
<tr>
<td>LVSP (mm Hg)</td>
<td>104.0 ± 11.2</td>
<td>95.5 ± 3.9</td>
<td>104.8 ± 5.7</td>
<td>96.8 ± 3.9</td>
<td>101.8 ± 21.2</td>
<td>97.9 ± 4.6</td>
</tr>
<tr>
<td>LVEDP (mm Hg)</td>
<td>11.2 ± 2.8</td>
<td>6.2 ± 3.2</td>
<td>15.2 ± 3.2</td>
<td>10.7 ± 1.9</td>
<td>16.5 ± 9.9</td>
<td>7.9 ± 2.3</td>
</tr>
<tr>
<td>dP/dt max (mm Hg/s)</td>
<td>5841 ± 803</td>
<td>6385 ± 462</td>
<td>5559 ± 496</td>
<td>5567 ± 668</td>
<td>6021 ± 1114</td>
<td>5510 ± 1302</td>
</tr>
<tr>
<td>dP/dt min (mm Hg/s)</td>
<td>5266 ± 1029</td>
<td>5890 ± 570</td>
<td>4945 ± 788</td>
<td>4733 ± 553</td>
<td>4648 ± 1099</td>
<td>4504 ± 1302</td>
</tr>
<tr>
<td>Ht (%)</td>
<td>46 ± 3</td>
<td>44 ± 2</td>
<td>60 ± 3***</td>
<td>48 ± 6**</td>
<td>59 ± 3***</td>
<td>56 ± 4</td>
</tr>
</tbody>
</table>

**TABLE 2**

<table>
<thead>
<tr>
<th></th>
<th>Nx (n = 11)</th>
<th>Nx + 4091 (n = 6)</th>
<th>Hx (n = 9)</th>
<th>Hx + 4091 (n = 11)</th>
<th>SuHx (n = 7)</th>
<th>SuHx + 4091 (n = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>b.wt. (g)</td>
<td>23 ± 3</td>
<td>26 ± 5</td>
<td>24 ± 3</td>
<td>23 ± 3</td>
<td>25 ± 3</td>
<td>26 ± 2</td>
</tr>
<tr>
<td>HR (bpm)</td>
<td>455 ± 71</td>
<td>508 ± 71</td>
<td>455 ± 36</td>
<td>466 ± 34</td>
<td>519 ± 19</td>
<td>468 ± 52</td>
</tr>
<tr>
<td>mAP (mm Hg)</td>
<td>87.7 ± 12.4</td>
<td>76.5 ± 4.0*</td>
<td>88.3 ± 6.7</td>
<td>85.4 ± 4.8</td>
<td>82.9 ± 15.3</td>
<td>85.0 ± 4.0</td>
</tr>
<tr>
<td>LVSP (mm Hg)</td>
<td>104.0 ± 11.2</td>
<td>95.5 ± 3.9</td>
<td>104.8 ± 5.7</td>
<td>96.8 ± 3.9</td>
<td>101.8 ± 21.2</td>
<td>97.9 ± 4.6</td>
</tr>
<tr>
<td>LVEDP (mm Hg)</td>
<td>11.2 ± 2.8</td>
<td>6.2 ± 3.2</td>
<td>15.2 ± 3.2</td>
<td>10.7 ± 1.9</td>
<td>16.5 ± 9.9</td>
<td>7.9 ± 2.3</td>
</tr>
</tbody>
</table>

**HR, heart rate; Ht, hematocrit.**

*P < 0.05; **P < 0.001; ***P < 0.0001, comparison with Nx; 1P < 0.05; **P < 0.01; ***P < 0.001, comparison with Hx; *P < 0.05; **P < 0.001; ***P < 0.0001, comparison with SuHx.
genes upregulated in the Hx group and HIF1A::ARNT, KLF4, and SP1 as the most enriched TFBS in genes upregulated in the Hx + SU group (Fig. 3B, top panels). HOXA5, PDX1, and PRRX2 were the most enriched TFBS in genes downregulated in the Hx and Hx + SU groups (Fig. 3B, bottom panels). Suppressor of fused (Sufu) and Cyp1a1 genes, respectively, upregulated >100- and >15-fold in lungs of mice exposed to Hx + SU, but not to Hx, and all genes downregulated >20-fold were common in lungs of mice exposed to Hx + SU and Hx (Fig. 3C).

G6PD Inhibition Decreased Expression of Cyp1a1 and Sufu Genes in Lungs of Mice and in Human PASMCs Exposed to Hx + SU. Next, we determined whether inhibition of G6PD activity decreases expression of Cyp1a1 and Sufu, which are increased in lungs of hypoxic mice (Fig. 3C) and Hx and Hx + SU mice and in human PASMCs exposed to Hx + SU. Treatment of PDD4091 (1.5 mg kg$^{-1}$ day$^{-1}$) for 3 weeks to mice and application of PDD4091 (1 μM) to human PASMCs for 48 hours rescinded the Hx + SU–induced Cyp1a1 and Sufu.
expression in lungs (Fig. 4, A and B) and in human PASMCs (Fig. 4C).

Methylation of DNA Is Decreased in Lungs of Hx and Hx + SU Mice. Epigenetic modifications are incriminated in the pathogenesis of PH (Cheng et al., 2019). Recently, we reported that downregulation of ten-eleven translocation 2 (Tet2) DNA demethylase in lungs of Hx Sv129J mice lacking the Cyp2c44 gene contributes to the genesis of PH and also demonstrated that inhibition of G6PD was ineffective in reducing PH in hypoxic Tet2−/− mice (Joshi et al., 2020). Therefore, we assumed that downregulation of Tet2 by Hx may augment DNA methylation in C57BL/6J mice and mediate maladaptive gene expression. Unexpectedly, we found that expression of Tet1, but not of Tet2 or Tet3, was reduced in lungs of C57BL/6J mice exposed to Hx vs. Nx and to Hx vs. Nx. RNA-seq was performed on three lungs in each group. Male = 2 and female = 1. For statistical analysis, the Benjamini-Hochberg method was applied for multiple test correction (FDR < 0.05).
or Dnmt1a, was decreased (Fig. 5A; Table 4). Concomitantly, in lungs of mice exposed to Hx as compared with Nx (Fig. 5B), we found that 45,321 CpG regions were differentially methylated, out of which 46.53% regions were hypermethylated and 53.47% were hypomethylated, whereas in lungs of mice exposed to Hx + SU as compared with Nx (Fig. 5C), 46,286 CpG regions were differentially methylated, out of which 46.15% regions were hypermethylated and 53.85% were hypomethylated. Therefore, there were 0.38% more hypomethylated and less hypermethylated CpG regions in lungs of Hx + SU versus Nx than Hx versus Nx C57BL/6J mice. Furthermore, two genes, Cyp1a1 and Kcng3, out of 12 upregulated genes (Fig. 3C), were hypomethylated in lungs of both Hx versus Nx and Hx + SU versus Nx C57BL/6J mice (Fig. 5D). It is noteworthy that CpG regions 2890 bp from the transcription start site of Cyp1a1 gene were hypomethylated in both Hx versus Nx and Hx + SU versus Nx groups (Fig. 5D), and G6PD inhibition hypermethylated Cyp1a1 and Kcng3 genes (Table 5).

**Discussion**

Pharmacologic inhibition of G6PD activity with the most selective and potent inhibitor synthesized so far to date, relaxed precontracted PA, decreased growth of PASMCs evoked by Hx and SU, reduced expression of Cyp1a1 and Sufu, and rescinded occlusion of PA in lungs of mice exposed to Hx + SU. Furthermore, the results of this study provided evidence that downregulation of the epigenetic modifiers Tett1 and Dnmt3b and hypomethylation of DNA altered gene expression in lungs of Hx and Hx + SU mice. Since a selective inhibitor of G6PD activity decreased occlusive remodeling of PA and alleviated RVSP/heart dysfunction evoked by Hx and Hx + SU in mice, without causing organ toxicity in Hx mice, we propose that G6PD might be a safe pharmacotherapeutic target to reduce precapillary PH.

Hx and Hx + SU mouse models are routinely used to study the pathology of PH (Stenmark et al., 2009). We observed in this study that mice exposed to Hx for 6 weeks and to Hx + SU for 3 weeks developed PH, which was more severe in the Hx + SU group than in the Hx group. In chronically Hx (3 weeks) mice, vasoconstriction and muscularization of small arteries, but not oblerrative remodeling of PA, contribute to increased pulmonary arterial pressure and RV pressure overload (Stenmark et al., 2009). The more severe PH in Hx + SU mice is attributed to the formation of angio-obliterative lesions in addition to vasoconstriction and muscularization (Vitali et al., 2014). Along with vascular pathology, RV pressure and contractility increased in the Hx and Hx + SU groups. Systemic blood pressure (mAP) and LV hemodynamic (LVSP, LVEDP, and dP/dt) was not significantly different in the Hx and Hx + SU groups compared with their control groups. Thus, our results indicate that inhibition of G6PD activity reduces both remodeling of PA and elevated RV pressure overload and hypertrophy in two different mouse models of PH.

The above observations raise the question of whether the underlying genetic/epigenetic determinants of PH in mice exposed to Hx and Hx + SU are the same or different. To seek answers, we performed RNA-seq analysis in lungs, which revealed that >1000 downregulated genes and only three upregulated genes, driven by different transcription factors, were common between the two models. Most strikingly, expression of Sufu and Cyp1a1 genes increased >15-fold in lungs of mice exposed to Hx + SU but not to Hx. Furthermore, exposure to SU increased expression of both Sufu and Cyp1a1 genes in Hx but not in Nx human PASMCs. Although these results are consistent with a recent study that indicates the HIF::ART-driven Cyp1a1 gene is upregulated in lungs of rats exposed to SU/Hx/Nx and in human PASMCs by SU (Dean et al., 2018), an increase of Sufu in lungs of PH mice and human PASMCs has not been reported. CYP1A1 is an

**Fig. 5.** DNA methylation in lungs of mice exposed to hypoxia and hypoxia + Sugen5416. (A) RNA-seq results disclosed that expression of Tett1 and Dnmt3b genes is significantly decreased in lungs of mice exposed to Hx and Hx + SU as compared with Nx. N = 3 in each group. Methylation of the DNA in lungs of mice exposed to Hx, Hx + SU was determined by reduced representation bisulfite sequencing method. (B and C) The pie graph demonstrates that more CpG regions are hypomethylated in lungs of Hx vs. Nx and Hx + SU vs. Nx mice. (D) Cyp1a1 and Kcng3 genes are hypomethylated in lungs of Hx and Hx + SU mice. The statistical differences in differential methylation between conditional groups was performed using the $\chi^2$ test and applying a q-value (SLIM) threshold of 0.05 and a methylation difference threshold of 25%.

**TABLE 4**

Expression of Dnmt and Tet genes in mouse lungs  
For statistical analysis, the Benjamini-Hochberg method was applied for multiple test correction (FDR < 0.05).

<table>
<thead>
<tr>
<th>Genes</th>
<th>Hx vs. Nx</th>
<th>Hx + SU/5419 vs. Nx</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Log2_fold</td>
<td>P Value</td>
</tr>
<tr>
<td>Dnmt1</td>
<td>−0.775</td>
<td>0.1700</td>
</tr>
<tr>
<td>Dnmt3a</td>
<td>0.086</td>
<td>0.8400</td>
</tr>
<tr>
<td>Dnmt3b</td>
<td>in.056</td>
<td>0.0028</td>
</tr>
<tr>
<td>Tett1</td>
<td>−2.219</td>
<td>0.0195</td>
</tr>
<tr>
<td>Tett2</td>
<td>0.628</td>
<td>0.2479</td>
</tr>
<tr>
<td>Tett3</td>
<td>0.212</td>
<td>0.4949</td>
</tr>
</tbody>
</table>
TABLE 5
Methylation status of Cyp1a1 and Kcnq3 genes in mouse lungs

<table>
<thead>
<tr>
<th>Condition</th>
<th>Gene Name</th>
<th>Strand</th>
<th>Distance from TSS</th>
<th>Differential Methylation</th>
<th>q-Value (SLIM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hx vs. Nx</td>
<td>ENSMUST00000034865.4_Cyp1a1</td>
<td>+</td>
<td>2890</td>
<td>-36.1</td>
<td>1.42E-05</td>
</tr>
<tr>
<td>Hx + SU vs. Nx</td>
<td>ENSMUST00000034865.4_Cyp1a1</td>
<td>+</td>
<td>4390</td>
<td>-41.4</td>
<td>2.25E-13</td>
</tr>
<tr>
<td>Hx + 4091 vs. Hx</td>
<td>ENSMUST00000034865.4_Cyp1a1</td>
<td>+</td>
<td>2890</td>
<td>36.1</td>
<td>7.35E-06</td>
</tr>
<tr>
<td>Hx vs. Nx</td>
<td>ENSMUST00000051482.1_Kcnq3</td>
<td>-</td>
<td>34,396</td>
<td>29.1</td>
<td>3.44E-14</td>
</tr>
<tr>
<td>Hx + SU vs. Nx</td>
<td>ENSMUST00000051482.1_Kcnq3</td>
<td>-</td>
<td>34,396</td>
<td>26.7</td>
<td>6.02E-07</td>
</tr>
<tr>
<td>Hx + 4091 vs. Hx</td>
<td>ENSMUST00000051482.1_Kcnq3</td>
<td>-</td>
<td>34,396</td>
<td>51.7</td>
<td>5.03E-26</td>
</tr>
</tbody>
</table>

estrogen-metabolizing enzyme that produces mitogenic metabolites of estrogen in human PASMCs (Dean et al., 2018), and SUFU is a negative regulator of hedgehog signaling, which controls cell proliferation during development in invertebrates and vertebrates ([Briscoe and Thérond, 2013]/Briscoe and Thérond, 2013; Liu, 2019). Increased CYP1A1 contributes to the pathogenesis of PH in SU/Hx/Nx rats (Dean et al., 2018). Our results suggest that increased CYP1A1 and SUFU signaling may have a potential role in the genesis of occlusive lesion formation in Hx + SU mice. Since transcription of CYP1A1 was abolished and that of SUFU was partially decreased in mouse lungs and in human PASMCs by G6PD inhibition, transcription of CYP1A1 and SUFU genes in lungs and PASMCs exposed to Hx + SU is potentially controlled by G6PD. Therefore, we propose that inhibition of G6PD activity could be useful in reversing the elevated expression of the pathogenic CYP1A1 and SUFU genes in PH.

We and others have recently proposed that DNA methylation and other epigenetic modifications potentially promote maladaptive gene expression, a determinant of inflammatory and hyperproliferative cell phenotype, in remodeled PA (Hu et al., 2019; Joshi et al., 2020; Potus et al., 2020). Furthermore, we recently showed that expression of Tet2, a DNA demethylase considered as a master regulator of differentiated fate of SMC phenotype (Liu et al., 2013), was downregulated in lungs of Sv129J mice with a Cyp2c44 gene knockout (Joshi et al., 2020). Therefore, we assumed that a loss of Tet1 modifies DNA methylation and initiates maladaptive gene expression in lungs of mice exposed to Hx and Hx + SU. Unexpectedly, expression of Tet1, but not of Tet2, and Dnmt3b was downregulated in lungs of C57BL/6J mice exposed to Hx and Hx + SU. We propose that genetic variations and differences in gene regulation observed between Sv129J and C57BL/6J mice (Hashimoto et al., 2020) may be a cause of Tet1 and Dnmt3b downregulation, but not of other isoforms of DNA demethylases and methyltransferases, in response to stress observed in C57BL/6J mice. Tet proteins are involved in the regulation of hematopoietic stem cell homeostasis and hematologic malignancies and diseases (Nakajima and Kunimoto, 2014). Although loss of a single TET protein is not sufficient to promote malignancies (An et al., 2015), TET1 and TET2 have been shown to, respectively, repress and promote osteogenesis and adipogenesis (Cakouros et al., 2019). Furthermore, inhibition of TET1 blocks expression of large-conductance Ca2+-activated K+ channel β1 subunit in uterine arteries of pregnant rats (Hu et al., 2017). Expression of this channel is a marker of differentiated SMCs. Therefore, we propose that downregulation of Tet1 could imply that 1) SMCs are dedifferentiated and 2) decreased Ca2+-activated K+ channels contribute to constrict PAs and increase pressure in lungs of Hx and Hx + SU mice.

Whereas inhibition of G6PD evoked hypomethylation and increased transcription of the many genes, expression of the Cyp1a1 gene, which promotes PASMC proliferation (Dean et al., 2018), was repressed through hypermethylation of the DNA in lungs of Hx and Hx + SU mice. Therefore, these results suggest that DNA methylation modulated by G6PD is functionally important in gene regulation and substantiate our previous finding that G6PD is a regulator of DNA methyltransferases and demethylase, which plays a crucial role in remodeling of PA (Joshi et al., 2020). In contrast, transcription of Sufu in mouse lungs evoked by Hx + SU was not regulated by the methylation of DNA. These results suggest G6PD inhibition activated other mechanisms of gene expression in addition to differential methylation of the DNA and that these mechanisms worked synergistically to regulate gene expression in lungs of Hx and Hx + SU mice.

In addition to arresting maladaptive gene expression in vascular cells of the PA wall and reducing cell growth in occlusive pulmonary arterial disease, PDD4091—a novel and selective inhibitor of G6PD activity (Hamilton et al., 2012)—dose-dependently relaxed precontracted PAs. We have previously shown that inhibition of G6PD activity with nonselective inhibitors, such as 17-ketosteroids [dehydroepiandrosterone (DHEA) and epiandrosterone, a DHEA metabolite], and siRNA-mediated knockdown of G6pd elicit relaxation of precontracted pulmonary artery (Gupte et al., 2002) and reduce RV pressures in hypertensive rats (Chettimada et al., 2012, 2015). Therefore, these studies and our current findings collectively suggest that G6PD inhibition reduces the elevated RV pressures and PH in Hx and Hx + SU mice by dilating PAs and reducing PA remodeling.

In conclusion, our results collectively demonstrate that G6PD activity is an important contributor to differential DNA methylation, maladaptive gene expression, and remodeling of PA in Hx and Hx + SU mice. The inhibition of G6PD activity by pharmacologic manipulations abrogated pulmonary vascular remodeling and improved the hemodynamics in mouse models of PH. Therefore, G6PD inhibitor N-[3β,5α]-17-oxoandrost-3-yl]sulfadime might be employed in the future as a pharmacotherapeutic agent to treat different forms of PH.
Kitagawa et al.

Authorship Contributions
Participated in research design: Kitagawa, McMurtry, Gupte.
Conducted experiments: Kitagawa, Jacob.
Contributed new reagents or analytic tools: Jordan, Waddell.
Performed data analysis: Kitagawa, Jacob, Gupte.
Wrote or contributed to the writing of the manuscript: Kitagawa, Jacob, McMurtry, Gupte.

References


Address correspondence to: Dr. Sachin A. Gupte, New York Medical College, BSB 546, 15 Dana Road, Valhalla, NY 10595. E-mail: sachin_gupte@yahoo.com or sgupte@nymed.edu